摘要肝细胞癌是最常见的原发性肝癌，也是全世界癌症相关死亡的主要原因之一。肝癌发病率高，病死率高，治疗手段有限，其防治面临很大挑战。目前介入治疗联合免疫靶向治疗具有协同增效作用，在延长患者生存时间及控制肿瘤方面疗效显著，给晚期肝癌患者带来全新治疗希望。笔者报道1例行肝动脉灌注化疗联合阿替利珠单克隆抗体+贝伐珠单克隆抗体治疗晚期肝细胞癌肺转移患者的临床经验。其研究结果显示：患者短期内肿瘤得到控制，临床疗效良好。

abstractsHepatocellular carcinoma (HCC) is one of the most common tumors of primary hepatic carcinoma, and one of the major causes of cancer related deaths worldwide. HCC has high incidence and mortality, with limited treatment. The prevention and treatment of HCC faces great challenges. At present, interventional therapy combined with immune plus targeted therapy has a synergistic effect and a significant effect in prolonging the survival time of patients and controlling tumors, which brings a brand-new therapeutic hope to patients with advanced HCC. The authors report a case of advanced HCC with lung metastasis who underwent hepatic arterial infusion chemotherapy combined with immune plus targeted therapy, with a result of good clinical effect on tumor controlling in a short time.